- Home
- PFD vs ACRS Comparison
PFD vs ACRS Comparison
Compare PFD & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- ACRS
- Stock Information
- Founded
- PFD 1990
- ACRS 2012
- Country
- PFD United States
- ACRS United States
- Employees
- PFD N/A
- ACRS N/A
- Industry
- PFD Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PFD Finance
- ACRS Health Care
- Exchange
- PFD Nasdaq
- ACRS Nasdaq
- Market Cap
- PFD 144.5M
- ACRS 127.6M
- IPO Year
- PFD N/A
- ACRS 2015
- Fundamental
- Price
- PFD $10.74
- ACRS $1.14
- Analyst Decision
- PFD
- ACRS Strong Buy
- Analyst Count
- PFD 0
- ACRS 7
- Target Price
- PFD N/A
- ACRS $11.67
- AVG Volume (30 Days)
- PFD 33.2K
- ACRS 968.2K
- Earning Date
- PFD 01-01-0001
- ACRS 05-06-2025
- Dividend Yield
- PFD 6.30%
- ACRS N/A
- EPS Growth
- PFD N/A
- ACRS N/A
- EPS
- PFD N/A
- ACRS N/A
- Revenue
- PFD N/A
- ACRS $18,720,000.00
- Revenue This Year
- PFD N/A
- ACRS N/A
- Revenue Next Year
- PFD N/A
- ACRS $425.96
- P/E Ratio
- PFD N/A
- ACRS N/A
- Revenue Growth
- PFD N/A
- ACRS N/A
- 52 Week Low
- PFD $8.53
- ACRS $0.95
- 52 Week High
- PFD $11.18
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PFD 43.75
- ACRS 27.21
- Support Level
- PFD $10.42
- ACRS $1.05
- Resistance Level
- PFD $10.96
- ACRS $1.23
- Average True Range (ATR)
- PFD 0.28
- ACRS 0.11
- MACD
- PFD -0.01
- ACRS -0.01
- Stochastic Oscillator
- PFD 46.85
- ACRS 16.82
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.